Mechanistic Modeling Improves Drug Discovery Workflows and Speeds Therapeutic Development

https://is1-ssl.mzstatic.com/image/thumb/Podcasts126/v4/a5/a2/ea/a5a2ead1-a365-5d95-9713-16f3db73bc3f/mza_2217280940514991596.jpeg/600x600bb.jpg

GEN Podcasts

Genetic Engineering and Biotechnology News

70 episodes

4 months ago

Genetic Engineering & Biotechnology News (GEN) has retained its position as the premier biotech publication since its launch in 1981. GEN publishes a print edition monthly and has additional exclusive editorial content online, including news and analysis as well as webinars, videos, and polls. GEN's unique news and technology focus covers the entire bioproduct life cycle, including drug discovery, early-stage R&D, applied research (e.g., omics, biomarkers, and diagnostics), bioprocessing, and commercialization.GEN's print magazine, which also can easily be accessed online, includes feature articles on emerging technologies, product roundups, in-depth overviews from key scientific and bioindustry meetings, and industry-standard tutorials and technical articles on drug discovery, bioprocessing, and assay technologies.

Hosted on Acast. See acast.com/privacy for more information.

All content for GEN Podcasts is the property of Genetic Engineering and Biotechnology News and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Hosted on Acast. See acast.com/privacy for more information.

Technology

Science,

Life Sciences

https://assets.pippa.io/shows/60f05d9c0626bc0012136b33/1669912699136-10ef0aa4480069d3f234d1348a70cd3f.jpeg

Mechanistic Modeling Improves Drug Discovery Workflows and Speeds Therapeutic Development

GEN Podcasts

23 minutes 6 seconds

2 years ago

Mechanistic Modeling Improves Drug Discovery Workflows and Speeds Therapeutic Development

This is the final episode in our three-part GENcast series, where we discuss the virtues of mechanistic modeling and how it can significantly impact critical decision-making points in the drug discovery process, especially as drug developers move closer toward the IND process. In our two previous podcasts, we were introduced to mechanistic modeling concepts and the basics of how they can be applied to drug discovery workflows. You can listen to the earlier podcasts with the following links: episode 1, episode 2. In this latest GENcast, I met up once again with Dr. John Burke, President, CEO, and Co-founder of Applied BioMath, to discuss the specific applications of mechanistic modeling, especially concerning the process of deciding the first human dose numbers, and how his company is helping biotech and pharma organizations reduce their late-stage drug attrition rates. Take a listen!

Hosted on Acast. See acast.com/privacy for more information.